MedPath

A multicentre, long-term administration study of KN01 in patients with mitochondrial encephalomyopathy(MELAS)

Phase 3
Conditions
motochondrial encephalomyopathy (MELAS)
Registration Number
JPRN-UMIN000015538
Lead Sponsor
Kawasaki Medical School Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patients can not be conducted by head MRI scan because of pacemaker implantation, etc. (2) Patients with severe coma or status epileptics (3) Patients incapable of communication due to dementia, bedridden, etc., (4) Patients with merger sepsis (5) Patients with severe impairment in cardiac, liver, or renal function (6) Patients in need of systemic administration of steroids for a long period of time (2 weeks or more) (7) Patients with pyruvate in 12 weeks before obtaining informed consent (8) Patients who are pregnant or lactating, or may be pregnant (9) Patients with history of hypersensitivity to the component of study drug (10)Ppatients with history of drug allergy (11) Patients who participated in clinical trials within 12 weeks before obtaining informed consent (12) Other, patients whom physician or investigator has determined disqualified as participants

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath